Table 3.
Logistic regression model of clinical features for predicting time to tumour progression (TTP)
| Parameter | n | TTP (months) Median | Min. | Max. | Univariate analysis* p value |
|---|---|---|---|---|---|
| BMI, kg/m2 | 0.004 | ||||
| <25 | 21 | 11.70 | 5.68 | 19.02 | |
| ≥25 | 33 | 6.00 | 1.38 | 17.74 | |
| CEA median (ng/ml) | 0.566 | ||||
| <28 | 34 | 9.49 | 1.38 | 18.60 | |
| ≥28 | 20 | 7.26 | 3.68 | 19.02 | |
| Age (years) | 0.264 | ||||
| <60 | 27 | 9.49 | 3.25 | 19.02 | |
| ≥60 | 27 | 7.00 | 1.38 | 17.74 | |
| Primary tumour | 0.618 | ||||
| Intact | 9 | 10.28 | 1.38 | 18.60 | |
| Non-intact | 45 | 7.52 | 2.00 | 19.02 | |
| K-ras mutation status | 0.683 | ||||
| Wild type | 25 | 9.49 | 1.38 | 17.74 | |
| Mutated | 29 | 7.00 | 3.25 | 19.02 | |
| Chemotherapy | 0.683 | ||||
| Irinotecan-based | 35 | 8.71 | 3.25 | 19.02 | |
| Oxaliplatin-based | 19 | 7.00 | 1.38 | 18.60 | |
| No. of disease sites | 0.032 | ||||
| <2 | 33 | 10.28 | 2.00 | 19.02 | |
| ≥2 | 21 | 5.72 | 1.38 | 17.74 |
In multivariate analysis, the only independent prognostic factor for TTP was BMI (p = 0.01; HR 4.37; 95 % CI 1.34–14.78) for patients with mCRC treated with combination chemotherapy and bevacizumab
* Mann–Whitney U test